NanoViricides advances measles drug program, files IND with FDA
1 report, 1 independent
Updated 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
NanoViricides, Inc. announced it is advancing its measles drug program toward clinical trials. The company is filing an investigational new drug application with the FDA. The drug, NV-387, is a novel antiviral that has completed juvenile animal model studies. It is not yet FDA-approved or commercially available.
From torontotelegraph.com
Why it matters
The advancement of NV-387 toward clinical trials could impact the financial performance of NanoViricides, Inc. The application is designed for use in specific severe cases of disease, such as Measles.
From torontotelegraph.com
Who's involved
- FDARegulatory agency reviewing the drug application
- United States of AmericaJurisdiction where the drug application is filed
Keep exploring
The entities involved
-
United States of America
vocal track by Kikki Danielsson; 1980 studio recording